BOT501 is a PDGF-ß-receptor targeted radionuclide-bicyclic peptide conjugate.
In the imaging diagnostic BOT501, a PET radionuclide is incorporated into the PDGF-ß-receptor binding bicyclic peptide. Conjugation procedures differ, appropriate for its specific application in a fibrotic organ. Further, dependent on the accumulation rate of the PET radionuclide-peptide complex and the background clearance rate in a fibrotic organ, the selected PET radionuclide can be 68Ga, 18F or 111In, among a few others.
Accumulation of BOT501 in PDGF-ß-receptor overexpressing cells has demonstrated to be disease-specific with functional signal/background ratios in heart, liver, lungs and kidneys.
In the RadioLigand Therapeutic version, 177Lu is conjugated to the BOT501 molecule. This therapeutic will be developed to treat patients with metastasized CMS4 colon cancer.